Filing Details

Accession Number:
0000899243-20-014282
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-05-26 21:27:41
Reporting Period:
2020-05-21
Accepted Time:
2020-05-26 21:27:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
730272 Repligen Corp RGEN Biological Products, (No Disgnostic Substances) (2836) 042729386
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1606030 Anthony Hunt C/O Repligen Corporation
41 Seyon St., Bldg 1, Ste 100
Waltham MA 02453
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-05-21 7,916 $16.55 238,157 No 4 M Direct
Common Stock Acquisiton 2020-05-21 39,037 $24.98 277,194 No 4 M Direct
Common Stock Disposition 2020-05-21 16,496 $139.17 260,698 No 4 S Direct
Common Stock Disposition 2020-05-21 28,980 $140.04 231,718 No 4 S Direct
Common Stock Disposition 2020-05-21 1,377 $140.99 230,341 No 4 S Direct
Common Stock Disposition 2020-05-21 100 $141.58 230,241 No 4 S Direct
Common Stock Acquisiton 2020-05-21 3,086 $32.40 233,327 No 4 M Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-05-21 7,916 $0.00 7,916 $16.55
Common Stock Stock Option (Right to Buy) Disposition 2020-05-21 39,037 $0.00 39,037 $24.98
Common Stock Stock Option (Right to Buy) Disposition 2020-05-21 3,086 $0.00 3,086 $32.40
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1 2024-05-05 No 4 M Direct
0 2025-02-26 No 4 M Direct
50,154 2027-02-23 No 4 M Direct
Footnotes
  1. Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 11, 2020.
  2. $139.17 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.52 to $139.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. $140.04 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.54 to $140.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. $140.99 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.54 to $141.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. This option is currently exercisable.